human gbm cell line u 87 mg  (ATCC)

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Differential transduction of human GBM cell lines with AAV vector serotypes (A) Representative images of U-87 MG and patient-derived cell lines transduced with AAV1, 2, 1/2, 6, and 6.2 expressing eGFP and pBS control-treated control. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Quantitation of the transduction efficiency for all serotypes in each cell line as determined by GFP expression. All data presented as mean (SD), n = 3 biological replicates.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Plasmid Preparation, Derivative Assay, Expressing, Control, Staining, Quantitation Assay

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV transduced CD44-positive cell populations with greater efficiency (A) Transduction efficiency of AAV1, 2, 1/2, 6, and 6.2 in CD44-positive and -negative cell populations. Two-way ANOVA showed no significant interaction between the effects of AAV serotype and CD44 expression on transduction efficiency in all cell lines. There was a significant main effect of CD44 expression in U-87 MG ( p = 0.007), case 1 ( p = 0.0003), and case 4 ( p = 0.010) but no statistical significance was found following Sidak’s multiple comparisons test. (B) CD44 expression in human GBM cell lines following AAV treatment. (C) Proliferation of the CD44-positive cell population normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Transduction, Expressing, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: Reductions in cell number and proliferation following AAV treatment persisted in the absence of transgene expression (A) Representative images of U-87 MG, cases 2 and 5 transduced with AAV expressing eGFP or no transgene, along with their respective pBS controls. Green, GFP expression; magenta, EdU staining; blue, Hoechst staining. Scale bars, 100 μm. (B) Total cell number and (C) cell proliferation in the 24 h prior to fixation, normalized to values from NTC-treated control. Treatments were compared against their respective pBS-treated control. All data presented as mean (SD), n = 3 biological replicates. Statistical significance is shown as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Expressing, Transduction, Staining, Control

Journal: Molecular Therapy Oncology

Article Title: AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation

doi: 10.1016/j.omton.2026.201216

Figure Lengend Snippet: AAV treatment induced cell-cycle arrest at G1 in cases 2 and 5 but not U-87 MG (A) Cumulative cytotoxicity was evaluated by LDH release assay 4 days following AAV treatment, normalized to the maximal LDH release from the Triton X-100 control. No statistical significance was detected. (B) Percentage of cells in each cell cycle phase (G0/G1, S, and G2/M) were quantified via DNA content profiling (see also ). All data presented as mean (SD), n = 3 biological replicates. Treatments were compared against their respective pBS-treated control. Statistical significance is shown as G0/G1 phases: ∗∗∗∗ p < 0.0001; S phase: † p < 0.05; G2/M phases: # p < 0.05, ### p < 0.001.

Article Snippet: The commercial human GBM cell line U-87 MG (ATCC) was plated at 5,000 cells per well in Eagle’s minimal essential medium (EMEM) (ATCC, 30–2003) supplemented with 10% FBS (Gibco, 10091148) and Penicillin-Streptomycin-Glutamine (Gibco, 10378016).

Techniques: Lactate Dehydrogenase Assay, Control

Journal: Nature Communications

Article Title: Iontronic click-to-release enables electrically controlled delivery of drugs and biomolecules beyond charge and size limitations

doi: 10.1038/s41467-026-70985-0

Figure Lengend Snippet: a Schematic of the synthesis and immobilization strategy for biotinylated CA4-prodrug ( 6 ), synthesized via sequential decoration of cTCO-bis-NHS ( 5 ). The biotin handle allows immobilization onto streptavidin-coated magnetic beads, forming a localized, iontronically activatable prodrug reservoir. IPs were positioned above the beads in a transwell insert containing U-87 cells in the lower chamber. Grey pills indicate inactive (bound) drug, blue (colored) pills indicate active drug. b 3D-printed platform designed to precisely position iontronic devices in standard 96-well transwell plates. c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 4 h at +20 nA (Active, n = 8) and at −20 nA (Reverse, n = 7) into transwells holding CA4-immobilized beads from ( a ). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 32), “No Beads” = operation of iontronic devices delivering 1 at +20 nA, no beads in transwell present ( n = 6), “No Tz 1 ” = CA4-immobilized beads in transwell present with iontronic delivery of K + (0.1 M KCl) instead of Tz 1 ( n = 8). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. No Beads (ns) = 0.2377; GC vs. No Tz 1 (ns) = 0.3827; GC vs. Reverse, 4 h (ns) = 0.5739, GC vs. Active, 4 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .

Article Snippet: The human GBM cell line U-87 (provided by the MUG Cell Bank, catalogue no. 300367, CLS) was cultured at 37 °C and 5% CO 2 in Eagle’s minimum essential medium (E-MEM) containing 10% fetal bovine serum (FBS), 4.5 g/L glucose, 2 mM L -glutamine, and 1% MEM Non-Essential Amino Acids.

Techniques: Synthesized, Magnetic Beads, Control

Journal: Nature Communications

Article Title: Iontronic click-to-release enables electrically controlled delivery of drugs and biomolecules beyond charge and size limitations

doi: 10.1038/s41467-026-70985-0

Figure Lengend Snippet: a Schematic overview of the bioorthogonal click-to-release (C2R) cascade of CA4-prodrug: Aminoethyl tetrazine (Tz 1 ) triggers the release of the cytotoxic agent combretastatin A-4 ( CA4 ) from sulfo-cTCO-DMEDA-CA4 ( 4 ) via a tetrazine-triggered elimination from TCO caged payload and self-immolation. b Dose-dependent cell viability of human glioblastoma cell line U-87 after 72 h incubation with the key components of the C2R reaction. Data represent mean ± SD of n = 3 independent biological replicates. Curves were fit using four-parameter logistic regression. Prodrug 4 (0.01–1000 nM, grey curve); parent CA4 (0.01–1000 nM, blue curve); released CA4 (0.01–1000 nM 4 + 5 µM 1, dashed blue curve); Tz 1 (5 µM, purple data point). c Cell viability of U-87 cells after operating iontronic devices delivering 1 for 1 h at +20 nA (Active, n = 9) and at −20 nA (Reverse, n = 11). Points represent individual biological replicates; bars indicate mean ± SD. GC growth control (untreated, n = 12). Statistical analysis was done via a Brown–Forsythe and Welch ANOVA tests (one-way) and Dunnett’s T3 multiple comparisons test. α = 0.05. p -values: GC vs. Reverse, 1 h (ns) = 0.5339; GC vs. Active, 1 h (****) = <0.0001. Certain graphical elements in ( a ) were created in BioRender. Hecko, S. (2026) https://www.BioRender.com/z8yr1eu .

Article Snippet: The human GBM cell line U-87 (provided by the MUG Cell Bank, catalogue no. 300367, CLS) was cultured at 37 °C and 5% CO 2 in Eagle’s minimum essential medium (E-MEM) containing 10% fetal bovine serum (FBS), 4.5 g/L glucose, 2 mM L -glutamine, and 1% MEM Non-Essential Amino Acids.

Techniques: Incubation, Control

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: IDH1 and IDH1 R132H expression in U-87 MG and U-87 MG IDH1 R132H . Quantification of IDH1 ( A ) and IDH1 R132H ( B ) normalized to GAPDH. Data are shown via interleaved bars plotting mean ± SD of n = 3 independent experiments; **** p -value < 0.0001 vs. IDH1.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Expressing

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Cell growth evaluation after B-SRCi exposure. Evaluation of cell growth 24 h after B-SRCi treatment exposure at 0.1 µM, 1 µM, 10 µM, and 100 µM of ( A ) in U-87 MG and ( B ) U-87 MG IDH1 R132H lines; data were shown via column mean, error bars and mean connected ± SD of n = 3 independent experiments; * p -value < 0.05; ** p -value < 0.01; **** p -value < 0.0001 vs. 0 μM.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques:

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Boron uptake measurement in U-87 MG and U-87 MG IDH1 R132H cell lines. Grayscale image of the sample (intensity 0–255) ( A , E ); 2D map of the 10 B concentration reconstructed using the calibration curve, expressed in ppm (color bar on the right) ( B , F ); histogram of the grayscale-level distribution (A.U.) within the analyzed area (the orange crosses indicate the main maxima (peaks) of the distribution, subsequently used to estimate the 10 B concentration) ( C , G ); histogram of the distribution of 10 B concentration values (ppm) corresponding to the pixels of the 2D map ( D , H ). The crosses mark the local maxima identified in the grayscale histogram. Each marked peak is used as a seed for a Gaussian fit performed in a neighborhood around the maximum, which provides a robust estimate of the peak position and amplitude for subsequent conversion to boron concentration.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Concentration Assay

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: pSRC (Tyr416) expression in U-87 MG and U-87 MG IDH1 R132H . ( A ) Quantification of pSRC protein normalized to GAPDH and ( B ) representative blots. Data are shown as interleaved bars plotting mean ± SD of n = 3 independent experiments; * p -value < 0.05 and ** p -value < 0.01.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Expressing

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Gene expression evaluation after B-SRCi exposure. Evaluation of gene expressions in U-87 MG and in U-87 MG IDH1 R132H lines exposed to 10 µM B-SRCi treatment 24 h; evaluation of ( A , B ) SRC, ( C , D ) BCL-2, ( E , F ) BAX, ( G , H ) CASP-3, and ( I , J ) CASPASE-8 in both cell lines; data are shown as interleaved bars, mean ± SD of n = 3 independent experiments; * p -value < 0.05; *** p -value < 0.001; **** p -value < 0.0001 vs. vehicle (0 μM).

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Gene Expression

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Immunofluorescence evaluation in U-87 MG and in U-87 MG IDH1 R132H lines exposed to 10 µM B-SRCi treatment 24 h; Ki-67 nuclear Corrected Total Cellular Fluorescence in Arbitrary Units (CTCF a.u.) of U-87 MG ( A , B ) and U-87 MG IDH1 R132H ( C , D ); CASP-3 cytoplasmic Corrected Total Cellular Fluorescence in Arbitrary Units (CTCF a.u.) of U-87 MG ( E , F ) and U-87 MG IDH1 R132H ( G , H ) data are shown as interleaved bars, mean ± SD of n = 3 independent experiments; ** p -value < 0.01; *** p -value < 0.001; **** p -value < 0.0001 vs. vehicle (0 μM). Nuclei are stained with DAPI (blue). Caspase and Ki67-positive cells are shown in green (Scale bar 20 μm).

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Immunofluorescence, Fluorescence, Staining

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Rate of cell growth of proton-irradiated U-87MG cell line in combination with B-SRCi. Evaluation of R.C.G. in U-87 MG cell line exposed to 10 µM B-SRCi combined with protons at doses of 1, 2, 4, and 5 Gy after 24 h ( A ), 48 h ( B ), and 72 h ( C ); data are plotted as points and connecting lines, with error bars showing the mean ± SD of n = 3 independent experiments; ** p -value < 0.01 and **** p -value < 0.0001 for Vehicle + radiation dose vs. 0 Gy Vehicle (sham-irradiated); # p -value < 0.05, ## p -value < 0.01, ### p -value < 0.001 and #### p -value < 0.0001 for B-SRCi + radiation dose vs. 0 Gy vehicle (sham-irradiated); R.C.G rate of cell growth.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Irradiation

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Rate of cell growth of the proton-irradiated U-87 MG IDH1 R132H cell line in combination with B-SRCi. Evaluation of R.C.G. in U-87 MG IDH1 R132H cell lines exposed to 10 µM B-SRCi combined with protons at doses of 1, 2, 4, and 5 Gy after 24 h ( A ), 48 h ( B ), and 72 h ( C ); data are plotted as points and connecting lines, with error bars showing the mean ± SD of n = 3 independent experiments; ** p -value < 0.01 and *** p -value < 0.001 for Vehicle + radiation dose vs. 0 Gy vehicle (sham-irradiated); ### p -value < 0.001 and #### p -value < 0.0001 for B-SRCi + radiation dose vs. 0 Gy vehicle (sham-irradiated); R.C.G rate of cell growth.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Irradiation

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Rate of cell growth of the X-ray-irradiated U87-MG cell line in combination with B-SRCi. Evaluation of R.C.G. in U-87 MG cell lines exposed to 10 µM B-SRCi combined with X-ray at 1, 2, 4, and 5 Gy after 24 h ( A ), 48 h ( B ), and 72 h ( C ); data are plotted as points and connecting lines, with error bars showing the mean ± SD of n = 3 independent experiments; * p -value < 0.05 for Vehicle + radiation dose vs. 0 Gy vehicle (sham-irradiated); ### p -value < 0.001 for B-SRCi + radiation dose vs. 0 Gy vehicle (sham-irradiated); R.C.G rate of cell growth.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Irradiation

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: Rate of cell growth of the X-ray-irradiated U-87 MG IDH1 R132H cell line in combination with B-SRCi. Evaluation of R.C.G. in U-87 MG IDH1 R132H cell lines exposed to 10 µM B-SRCi combined with X-ray at 1, 2, 4, and 5 Gy after 24 h ( A ), 48 h ( B ), and 72 h ( C ); data are plotted as points and connecting lines, with error bars showing the mean ± SD of n = 3 independent experiments; ++++ p -value < 0.0001, +++ p -value < 0.001 and ++ p -value < 0.01 for Vehicle vs. B-SRCi at the same dose; * p -value < 0.05, ** p -value < 0.01 and **** p -value < 0.0001 for Vehicle + radiation dose vs. 0 Gy vehicle (sham-irradiated); # p -value < 0.05, ### p -value < 0.001 and #### p -value < 0.0001 for B-SRCi + radiation dose vs. 0 Gy vehicle (sham-irradiated); R.C.G rate of cell growth.

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Irradiation

Journal: Pharmaceuticals

Article Title: Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1 R132H Glioma Cell Lines

doi: 10.3390/ph19030392

Figure Lengend Snippet: DNA damage by γH2A.X evaluation 30 min after X-ray and proton irradiation of U87-MG and the cell line in combination with B-SRCi. Evaluation of mean number of γH2A.X per nucleus in U-87 MG cell lines ( A ) and representative images ( B ) 30 min after irradiation with X-rays and protons at 2 Gy with and without 10 µM B-SRCi treatment; data are shown as a scatter plot, mean ± SD of n = 3 independent experiments; **** p -value < 0.0001 and *** p -value < 0.001, vs. 0 Gy vehicle (sham-irradiated); #### p -value < 0.0001 and # p -value < 0.05, vs. B-SRCi; +++ p -value < 0.001. Nuclei are stained with DAPI (blue). γH2AX foci are detected in red (anti-rabbit IgG–Atto 594). Scale bar 20 μm (5 μm for ROI).

Article Snippet: U-87 MG human GBM cell lines were purchased from American Type Culture Collections (ATCC, Manassas, VA, USA).

Techniques: Irradiation, Staining

Journal: bioRxiv

Article Title: Multi‑omic and spatial analysis reveals tumour‑derived paracrine signals drive suppressive macrophage polarisation via activation of the cAMP-CREB axis in glioblastoma

doi: 10.64898/2026.02.19.706754

Figure Lengend Snippet: (A) Western blot of THP-1 differentiated macrophages stimulated for 30 min, with conditioned media (CM) from a panel of GBM cell lines and probed using antibodies for, total CREB, phospho-CREB (pCREB) and b-actin. Data shown is representative of three independent experiments. (B) CREB transactivation activity in THP-1 macrophages transfected with a CREB luciferase reporter plasmid after stimulation with MU41 GBM cell conditioned medium (CM). CREB activity is presented as Relative Light Units (RLU) per mg of protein lysate. Statistical significance was determined using one-way ANOVA, followed by Tukey’s test for multiple comparisons (a=0.05). *(p<0.05). Error bars are median ± interquartile range. (C) Expression of CD2026 in THP-1 differentiated macrophages incubated with or without GBM cell (MU41) conditioned medium (CM) in the presence or absence of the CREB inhibitor (CREBi), 666-15 (1mM). (D) Multiplex IHC image showing phospho-AKT (pAKT), phospho-ERK1/2 (pERK) and pCREB expression in BMDM-TAMs in GBM tissue. Scale bar is 50mm. (E) Percentage of CD68 + pCREB + MDM co-expressing pAKT and pERK1/2 in GBM tissue (n=3). Error bars are S.E.M. (F) Cell lysates from THP-1 differentiated macrophages were probed for expression of pCREB, CREB, b-actin, pAKT, AKT, pERK and ERK following a 30-minute stimulation with GBM-CM, in combination with either a PI3K inhibitor (PI3Ki) BKM-120 (2 mM), a MAPK inhibitor (MAPKi) U0126 (10 mM), a cAMP inhibitor (cAMPi) H89 (10 mM) and a CREB inhibitor (CREBi) 666-15 (1 mM). MU41-CM with DMSO, and DMSO in fresh media (RPMI) ‘medium/med’, are negative controls, basal medium without GBM-CM.

Article Snippet: Human GBM cell lines (U-87MG, LN-229, LN-18, U-118MG, T98G, A172) obtained from the ATCC, and patient-derived GBM cells (MU41) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific) with 10% fetal calf serum (FCS) (Bovogen, Australia, #SFBS-F) and penicillin-streptomycin-amphotericin B (Gibco Anti-Anti, Thermo Fisher Scientific).

Techniques: Western Blot, Activity Assay, Transfection, Luciferase, Plasmid Preparation, Expressing, Incubation, Multiplex Assay